After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Weight loss drugs like Ozempic, Zepbound and Wegovy are surging in popularity. Now, a new pill from Eli Lilly has taken a ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and ...

Illustration: Elizabeth Smelov The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes ...

Smaller biotechnology companies, and large pharmaceutical rivals including AstraZeneca Plc, are still working on their own weight-loss pills, with varying degrees of success. Lilly, which was ...

The pill, poised to revolutionize the weight loss world, may be up for FDA approval in late 2025. A daily pill to rival Ozempic is one step closer to hitting the market. Pharmaceutical giant Eli ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions. The pill form could expand access and reduce costs compared with injectable GLP-1 drugs. The move ...

Lilly said weight loss hadn’t plateaued at the time the study ended, suggesting that patients might lose more weight. The pill lowered blood sugar levels by an average of 1.3%. Ozempic lowered ...

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved. An experimental once-daily pill appears to ...